Literature DB >> 28520528

Expanding the Roster of ROS1 Inhibitors.

Ibiayi Dagogo-Jack1, Alice T Shaw1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28520528     DOI： 10.1200/JCO.2017.73.2586

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.

Authors:  Fernando Vargas-Madueno; Edwin Gould; Raul Valor; Nhu Ngo; Linsheng Zhang; Miguel A Villalona-Calero
Journal:  Oncologist       Date:  2018-05-08

2.  Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.

Authors:  Kartik Sehgal; Rushad Patell; Deepa Rangachari; Daniel B Costa
Journal:  Transl Cancer Res       Date:  2018-08       Impact factor: 1.241

Review 3.  Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.

Authors:  Muhammad Latif; Zaman Ashraf; Sulman Basit; Abdul Ghaffar; Muhammad Sohail Zafar; Aamer Saeed; Sultan Ayoub Meo
Journal:  RSC Adv       Date:  2018-05-04       Impact factor: 4.036

4.  Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Authors:  D G Bebb; J Agulnik; R Albadine; S Banerji; G Bigras; C Butts; C Couture; J C Cutz; P Desmeules; D N Ionescu; N B Leighl; B Melosky; W Morzycki; F Rashid-Kolvear; Clin Lab; H S Sekhon; A C Smith; T L Stockley; E Torlakovic; Z Xu; M S Tsao
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

5.  Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.

Authors:  Yuka Kato; Kiichiro Ninomiya; Kadoaki Ohashi; Shuta Tomida; Go Makimoto; Hiromi Watanabe; Kenichiro Kudo; Shingo Matsumoto; Shigeki Umemura; Koichi Goto; Eiki Ichihara; Takashi Ninomiya; Toshio Kubo; Akiko Sato; Katsuyuki Hotta; Masahiro Tabata; Shinichi Toyooka; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Cancer Sci       Date:  2018-09-11       Impact factor: 6.716

Review 6.  Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.

Authors:  Swapnil Rajurkar; Isa Mambetsariev; Rebecca Pharaon; Benjamin Leach; TingTing Tan; Prakash Kulkarni; Ravi Salgia
Journal:  J Clin Med       Date:  2020-06-15       Impact factor: 4.241

Review 7.  Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.

Authors:  Alberto D'Angelo; Navid Sobhani; Robert Chapman; Stefan Bagby; Carlotta Bortoletti; Mirko Traversini; Katia Ferrari; Luca Voltolini; Jacob Darlow; Giandomenico Roviello
Journal:  Cancers (Basel)       Date:  2020-11-06       Impact factor: 6.639

8.  Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.

Authors:  Amanda J W Gibson; Adrian Box; Winson Y Cheung; Michelle L Dean; Anifat A Elegbede; Desiree Hao; Aliyah Pabani; Randeep Sangha; Dafydd Gwyn Bebb
Journal:  Curr Oncol       Date:  2022-03-14       Impact factor: 3.677
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.